[{"AccountsPayableCurrent_0_Q3_USD":2185000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":187000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":8180000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":7467000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":1014000.0,"OperatingIncomeLoss_3_Q3_USD":-69802000.0,"OperatingIncomeLoss_1_Q3_USD":-26683000.0,"OperatingExpenses_3_Q3_USD":69802000.0,"OperatingExpenses_1_Q3_USD":26683000.0,"NonoperatingIncomeExpense_3_Q3_USD":11576000.0,"OtherAssetsNoncurrent_0_Q3_USD":193000.0,"NonoperatingIncomeExpense_1_Q3_USD":4216000.0,"NetIncomeLoss_3_Q3_USD":-58226000.0,"NetIncomeLoss_1_Q3_USD":-22467000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-51345000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":45426000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":1443000.0,"MarketableSecuritiesRealizedGainLoss_3_Q3_USD":-296000.0,"LiabilitiesNoncurrent_0_Q3_USD":7467000.0,"LiabilitiesCurrent_0_Q3_USD":9649000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":225052000.0,"NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_3_Q3_USD":19000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q3_USD":435000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q3_USD":-445000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q3_USD":-619000.0,"StockIssuedDuringPeriodValueEmployeeBenefitPlan_1_Q3_USD":773000.0,"StockholdersEquity_0_Q3_USD":207936000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3_Q3_USD":3185000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-226062000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":50954000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":19738000.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":2215000.0,"ProfitLoss_3_Q3_USD":-58226000.0,"ProceedsFromStockPlans_3_Q3_USD":1443000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3_Q3_USD":-430000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3_Q3_USD":130686000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":845000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_3_Q3_USD":84415000.0,"OtherNonoperatingIncomeExpense_3_Q3_USD":11283000.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":4156000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":-773000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":-350000.0,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_3_Q3_USD":-296000.0,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1_Q3_USD":-176000.0,"OtherComprehensiveIncomeLossNetOfTax_3_Q3_USD":-907000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":8388000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":24479660.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q3_USD":1511000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q3_USD":1585000.0,"CommitmentsAndContingencies_0_Q3_USD":null,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":-5015000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q3_USD":45577000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q3_USD":12094000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":45577000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q3_USD":149212000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q3_USD":149212000.0,"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0_Q3_USD":109859000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q3_USD":149889000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.001,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q3_USD":680000.0,"AssetsCurrent_0_Q3_USD":214464000.0,"Assets_0_Q3_USD":225052000.0,"AmortizationOfDebtDiscountPremium_3_Q3_USD":2081000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":8432000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":2777000.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":436313000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":-2339000.0,"AccruedProfessionalFeesCurrent_0_Q3_USD":596000.0,"AccruedLiabilitiesCurrent_0_Q3_USD":6450000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q3_USD":3000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q3_USD":1547000.0,"CommonStockSharesAuthorized_0_Q3_shares":100000000.0,"CommonStockSharesOutstanding_0_Q3_shares":24537094.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q3_USD":1631000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q3_USD":11430000.0,"InvestmentIncomeInterest_3_Q3_USD":822000.0,"InvestmentIncomeInterest_1_Q3_USD":258000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":3659000.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":-279000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":228000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":18848000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":6945000.0,"CommonStockSharesIssued_0_Q3_shares":24537094.0,"ForeignCurrencyTransactionGainLossRealized_3_Q3_USD":-698000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q3_USD":-198000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":3252000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_Q3_USD":-539000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-2.38,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.92,"DepreciationDepletionAndAmortization_3_Q3_USD":408000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-59133000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-23086000.0,"CommonStockValue_0_Q3_USD":24000.0,"ForeignCurrencyTransactionGainLossBeforeTax_3_Q3_USD":-529000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":24449788.0,"Ticker":"KALV","CIK":"1348911","name":"KALVISTA PHARMACEUTICALS, INC.","OfficialName":"KalVista Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20220131","fy":"2022.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"339433230.0","Country":"United Kingdom","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20220310"}]